- Home
- DBRG vs NRIX Comparison
DBRG vs NRIX Comparison
Compare DBRG & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DBRG | NRIX |
|---|---|---|
| Founded | 1991 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.5B |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DBRG | NRIX |
|---|---|---|
| Price | $15.92 | $26.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $16.00 | ★ $30.50 |
| AVG Volume (30 Days) | ★ 3.4M | 1.0M |
| Earning Date | 05-12-2026 | 04-08-2026 |
| Dividend Yield | ★ 0.26% | N/A |
| EPS Growth | ★ 557.14 | N/A |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $93,959,000.00 | $76,987,000.00 |
| Revenue This Year | $373.39 | N/A |
| Revenue Next Year | $8.23 | $48.05 |
| P/E Ratio | $13.49 | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $8.94 | $8.20 |
| 52 Week High | $15.98 | $28.23 |
Technical Indicators
Market Signals| Indicator | DBRG | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 51.26 | 52.95 |
| Support Level | $15.33 | $14.63 |
| Resistance Level | N/A | $28.23 |
| Average True Range (ATR) | 0.03 | 1.02 |
| MACD | -0.01 | -0.26 |
| Stochastic Oscillator | 40.00 | 34.45 |
Price Performance
Historical ComparisonAbout DBRG DigitalBridge Group Inc.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.